Journal of Applied Pharmaceutical Science · 2020 · 16 citations · 7 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibiotic ResistanceAntimicrobial TherapyClinical BacteriologyMedical BacteriologyResistance In Gram-negative BacteriaUrinary Tract InfectionsAntibiotic Resistance In UropathogensAntimicrobial Resistance In Urinary Tract InfectionsCommunity-acquired Urinary Tract InfectionNosocomial Urinary Tract InfectionsResistance Mechanisms In Gram-negative BacteriaTertiary Care OrganizationUrinary Tract Infection Antibiotic TherapyUropathogenic Escherichia Coli
This study sought to investigate the prevalence of colistin-resistant Gram-negative bacteria (CoR-GNB) among Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae isolated from patients with bacteremia and to identify other antimicrobials as a potential therapy for CoR-GNB infections. We retrospectively reviewed the data of non-repeated clinical bacterial isolates from patients admitted to Phramongkutklao Hospital during May 2017-April 2018. We obtained the minimum inhibitory concentrations (MICs) of the studied isolates and interpreted the MIC values followed by the Clinical and Laboratory Standards Institute (CLSI) criteria. Out of 623 bacterial isolates, the prevalence of E. coli was predominantly high (349), followed by K. pneumoniae (150), P. aeruginosa (64), and A. baumannii (60). The CoR-GNB rates among E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa were 2.9%, 17.3%, 5.0%, and 1.6%, respectively. Seven out of 26 colistin-resistant K. pneumoniae isolates and seven out of 10 colistin-resistant E. coli isolates were still susceptible to carbapenems (the MICs for imipenem and meropenem were 1 g/ml). Tigecycline and aminoglycosides might be the best therapeutic choices against CoR-GNB. In conclusion, our findings confirmed a CoR-GNB prevalence of approximately 1.6%-17.3%, depending on the bacterial species. Certain available antimicrobials remain effective against CoR-GNB.
7
Alessandro Capone, Maddalena Giannella, D. Fortini et al. · Clinical Microbiology and Infection · 2012 · 360 citations
Ana Cristina Gales, Ronald N. Jones, Hélio S. Sader · Journal of Antimicrobial Chemotherapy · 2011 · 338 citations · Full text
Hélio S. Sader, David J. Farrell, Robert K. Flamm et al. · International Journal of Antimicrobial Agents · 2014 · 254 citations
Hélio S. Sader, Mariana Castanheira, Robert K. Flamm et al. · Diagnostic Microbiology and Infectious Disease · 2015 · 69 citations